Malignant hematologic diseases in adolescents and young adults

Wood, William A.; Lee, Stephanie J.

doi:10.1182/blood-2010-12-283093

Cited by 103 publications

(109 citation statements)

References 134 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…36,[42][43][44][45] With an oral, self-administered therapy that is given for long (indefinite) periods of time, such as TKIs in CML, non-adherence becomes an even bigger issue. A multitude of other concerns should be considered for the AYA population including fertility, 46,47 pharmacology and metabolism, development of late effects of treatment including secondary neoplasms, and access to health insurance and health care. These are all, indeed, considerations that have a huge impact on outcomes in this unique population.…”

Section: Discussionmentioning

confidence: 99%

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

Pemmaraju¹,

Kantarjian²,

Shan³

et al. 2012

Haematologica

View full text Add to dashboard Cite

BackgroundOutcomes in chronic myeloid leukemia have improved with tyrosine kinase inhibitor treatment. However, little is known about outcomes of chronic myeloid leukemia in adolescent and young adult patients. Design and MethodsWe reviewed all 468 chronic myeloid leukemia patients treated at our institution with tyrosine kinase inhibitors as initial therapy: imatinib (n=281), nilotinib (n=98) or dasatinib (n=89). ResultsMedian age was 47 years, median follow up 71 months and median treatment time with initial tyrosine kinase inhibitors 48 months. Adolescent and young adult was defined as aged 15-29 years. Sixty-one adolescent and young adult patients were identified. The only significant differences between adolescent and young adult and older patients were incidence of splenomegaly and distribution in Sokal risk groups. Only 3 adolescent and young adult patients have died. Rates of complete cytogenetic, major molecular and complete molecular response were significantly higher in older patients compared to adolescent and young adult patients, with a favorable trend in event-free survival for older patients. Transformation-free and overall survival were similar for the two groups. ConclusionsThe unfavorable trend in outcome for adolescent and young adult patients with chronic myeloid leukemia is unexpected. Additional research in this population is required to better define outcomes, understand the cause of this difference, and to help make better treatment recommendations.Key words: chronic myelogenous leukemia, tyrosine kinase inhibitor, adolescent, young adult, outcome. Haematologica 2012;97(7):1029-1035. doi:10.3324/haematol.2011 This is an open-access paper. Citation: Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, and Cortes J. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Analysis of outcomes in adolescents and

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

Pemmaraju¹,

Kantarjian²,

Shan³

et al. 2012

Haematologica

View full text Add to dashboard Cite

show abstract

“…56,57 It is possible that these cognitive, emotional, behavioral, and family dynamic concerns may be associated with adherence. 36,56,[58][59][60][61][62] The influence of peer relationships on adherence, compared with those with parents and providers, should also be further examined for adolescents diagnosed with cancer. Adolescents may be positively or negatively motivated to engage in certain behaviors based on the need for acceptance by their peer groups.…”

Section: Psychosocial Barriers and Facilitators Affecting Adherence Tmentioning

confidence: 99%

Psychosocial Barriers and Facilitators to Clinical Trial Enrollment and Adherence for Adolescents With Cancer

et al. 2014

View full text Add to dashboard Cite

have not experienced the same survival gains as children and older adults diagnosed with cancer. Poor clinical trial enrollment and adherence rates among adolescents may account for some of this disparity. Although biological, regulatory, systemic, and practice-related challenges to clinical trial enrollment and adherence have been examined, studies of psychosocial factors, which can serve as barriers or facilitators to enrollment and adherence, are limited. To bring attention to these psychological factors, we reviewed existing literature on psychosocial barriers and facilitators that can affect an adolescent' s decision to enroll and adhere to a clinical trial. We also provide potential strategies to address psychosocial factors affecting clinical trial accrual and adherence. Pediatrics

show abstract

“…A social component could be integrated into this design so that participants could monitor and support one another, and to the extent that these PGHD data are collected in a decentralized way, virtual web-based recruitment and enrollment strategies could be considered. These features might be attractive to technology-savvy individuals who are traditionally difficult to enroll onto clinical trials, such as adolescents and young adults (Wood and Lee, 2011).…”

Section: Matching Pghd Sources To Therapeutic Indicationsmentioning

confidence: 99%

Emerging uses of patient generated health data in clinical research

2014

Self Cite

View full text Add to dashboard Cite

Quality of careClinical trials A B S T R A C TRecent advancements in consumer directed personal computing technology have led to the generation of biomedically-relevant data streams with potential health applications.This has catalyzed international interest in Patient Generated Health Data (PGHD), defined as "health-related data e including health history, symptoms, biometric data, treatment history, lifestyle choices, and other information-created, recorded, gathered, or inferred by or from patients or their designees (i.e. care partners or those who assist them) to help address a health concern."(Shapiro et al., 2012) PGHD offers several opportunities to improve the efficiency and output of clinical trials, particularly within oncology. These range from using PGHD to understand mechanisms of action of therapeutic strategies, to understanding and predicting treatment-related toxicity, to designing interventions to improve adherence and clinical outcomes. To facilitate the optimal use of PGHD, methodological research around considerations related to feasibility, validation, measure selection, and modeling of PGHD streams is needed. With successful integration, PGHD can catalyze the application of "big data" to cancer clinical research, creating both "n of 1" and population-level observations, and generating new insights into the nature of health and disease.

show abstract

Malignant hematologic diseases in adolescents and young adults

Cited by 103 publications

References 134 publications

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

Psychosocial Barriers and Facilitators to Clinical Trial Enrollment and Adherence for Adolescents With Cancer

Emerging uses of patient generated health data in clinical research

Contact Info

Product

Resources

About